 "Dr Reddys Lab dips on disappointing Q1 earnings")
Dr Reddys Laboratories has dipped 5% to Rs 3,305 on the BSE in intra-day trade after the drug maker reported a consolidated net profit of Rs 154 crore for the quarter ended June 30, 2016 (Q1FY17), against Rs 626 crore in the same quarter year ago.
Revenues declined by 14% to Rs 3,235 crore in June quarter against Rs 3,758 crore in the corresponding quarter of previous fiscal.
Analysts on an average had expected profit of Rs 466 crore on revenues of Rs 3,779 crore for the quarter.
GV Prasad, Co-chairman and CEO said, “The Company’s top and bottom lines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela.
We also faced a number of challenges in the quarter including price erosion and delayed in launches as a result of the warning letter, which significantly impacted company’s earnings. We remain focused on generating long term, sustainable growth, he added.
At 03:16 PM, the stock was down 4.4% at Rs 3,322 on the BSE, as compared to 0.54% decline in the S&P BSE Sensex. A combined 1.42 million shares changed hands on the counter on the BSE and NSE so far.
Revenues declined by 14% to Rs 3,235 crore in June quarter against Rs 3,758 crore in the corresponding quarter of previous fiscal.
Analysts on an average had expected profit of Rs 466 crore on revenues of Rs 3,779 crore for the quarter.
GV Prasad, Co-chairman and CEO said, “The Company’s top and bottom lines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela.
We also faced a number of challenges in the quarter including price erosion and delayed in launches as a result of the warning letter, which significantly impacted company’s earnings. We remain focused on generating long term, sustainable growth, he added.
At 03:16 PM, the stock was down 4.4% at Rs 3,322 on the BSE, as compared to 0.54% decline in the S&P BSE Sensex. A combined 1.42 million shares changed hands on the counter on the BSE and NSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%